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Focal adhesion kinase (FAK) promotes anti-tumor
immune evasion. Specifically, the kinase activity of
nuclear-targeted FAK in squamous cell carcinoma
(SCC) cells drives exhaustion of CD8+ T cells and
recruitment of regulatory T cells (Tregs) in the tumor
microenvironment by regulating chemokine/cytokine
and ligand-receptor networks, including via tran-
scription of Ccl5, which is crucial. These changes
inhibit antigen-primed cytotoxic CD8+ T cell activity,
permitting growth of FAK-expressing tumors. Mech-
anistically, nuclear FAK is associated with chromatin
and exists in complex with transcription factors and
their upstream regulators that control Ccl5 expres-
sion. Furthermore, FAK’s immuno-modulatory nu-
clear activities may be specific to cancerous squa-
mous epithelial cells, as normal keratinocytes do
not have nuclear FAK. Finally, we show that a
small-molecule FAK kinase inhibitor, VS-4718, which
is currently in clinical development, also drives
depletion of Tregs and promotes a CD8+ T cell-medi-
ated anti-tumor response. Therefore, FAK inhibitors
may trigger immune-mediated tumor regression,
providing previously unrecognized therapeutic
opportunities.INTRODUCTION
First described more than a decade ago (Onizuka et al., 1999;
Shimizu et al., 1999), regulatory T cells (Tregs) have become
recognized as a core component of the immuno-suppressive ar-
mory utilized by many tumors to keep the anti-tumor activity of
antigen-primed CD8+ T cells at bay. Increased Treg numbers
has been associated with poorer survival in ovarian (Curiel160 Cell 163, 160–173, September 24, 2015 ª2015 The Authorset al., 2004), gastrointestinal (Sasada et al., 2003), and esopha-
geal (Kono et al., 2006) cancer. Indeed, the ratio of CD8+
T cells/Tregs correlates with poor prognosis, shifting the balance
from anti-tumor immunity toward tumor tolerance (Quezada
et al., 2006; Sato et al., 2005; Shah et al., 2011). Through
secreting a range of chemokines and cytokines, cancer cells
can promote the recruitment of Tregs into tumors and can also
facilitate their peripheral expansion and retention (Darrasse-
Je`ze and Podsypanina, 2013; Ondondo et al., 2013). Thus, Tregs
can act as a barrier to effective immune-based therapy aimed at
activation of a CD8+ T cell anti-tumor immune response. How-
ever, the specific signals within tumor cells that stimulate
elevated intra-tumoral Tregs, giving rise to tumor tolerance,
remain elusive.
FAK is a tyrosine kinase that regulates diverse cellular func-
tions, including adhesion, migration, invasion, polarity, prolifera-
tion, and survival (Frame et al., 2010). Using targeted gene dele-
tion in mouse skin, we have previously shown a requirement for
fak in tumor initiation and progression to malignant disease
(McLean et al., 2004). FAK is also required for mammary tumor
progression, intestinal tumorigenesis, and the androgen-inde-
pendent formation of neuroendocrine carcinoma in a mouse
model of prostate cancer (Ashton et al., 2010; Lahlou et al.,
2007; Luo et al., 2009a; Provenzano et al., 2008; Pylayeva
et al., 2009; Slack-Davis et al., 2009). Expression of FAK is
elevated in a number of tumor types (reviewed in McLean
et al., 2005), and FAK inhibitors are being developed as potential
cancer therapeutics (Roberts et al., 2008; Shapiro et al., 2014).
Many of FAK’s functions in cancer are via its role in signaling
downstream of integrins and growth factor receptors at the
plasma membrane. FAK also contains putative nuclear localiza-
tion sequences (NLS) within the F2 lobe of its FERM domain and
can localize to the nucleus upon receipt of cellular stress, where
it binds to p53 (Lim et al., 2008). However, the extent of FAK’s nu-
clear functions remains largely unknown. Here, we report a func-
tion for nuclear FAK in regulating transcription of inflammatory
cytokines and chemokines, in turn promoting an immuno-sup-
pressive, pro-tumorigenic microenvironment. This is mediated
Figure 1. Loss of FAK or FAK Kinase Activ-
ity Results in CD8+ T Cell-Dependent SCC
Tumor Clearance
(A and B) SCC FAK-WT and SCC FAK/ subcu-
taneous tumor growth in immune-deficient CD-1
nude mice (A) and immune-competent FVB
mice (B).
(C and D) SCC FAK/ (C) and SCC FAK-WT (D)
tumor growth in FVB mice treated with T-cell-
depleting antibodies.
(E)Secondary tumor re-challengewithSCCFAK/
(top) and SCC FAK-WT (middle) cells following a
pre-challenge with SCC FAK/ cells and a 7-day
tumor-free period. Subcutaneous growth of SCC
FAK-WT and SCC FAK/ tumors injected at day
28 without pre-challenge (bottom).
(F) Tumor growth in FVB mice following subcu-
taneous injection of SCC FAK-WT, SCC FAK/,
and SCC FAK-KD cells.
*p < 0.05, **p or ++p < 0.01, ****p < 0.0001; Sidak-
corrected two-way ANOVA (A and B) or Tukey-
corrected two-wayANOVA (C,versusSCCFAK/;
D, versus SCC FAK-WT; F, *, versus SCC FAK/
and +, versus SCC FAK-KD). Data are represented
as mean ± SEM; n = 5–6 tumors.by recruitment and expansion of Tregs via FAK-regulated che-
mokine/cytokine networks, and we have found an important
role for Ccl5 and TGFb2. Therefore, FAK controls the tumor envi-
ronment, and suppressing FAK activity, including via a clinically
relevant FAK inhibitor, may be therapeutically beneficial by trig-
gering immune-mediated tumor regression.
RESULTS
FAK-Deficient SCC Tumors Undergo Regression in
an Immune-Competent Host
We used a syngeneic model of SCC in which the fak gene had
been deleted by Cre-lox recombination (McLean et al., 2004;
Serrels et al., 2012) and mutant tumor cell lines generated. We
monitored tumor growth following injection of 13 106 FAK-defi-
cient cells (FAK/) or FAK-deficient cells that re-expressed
wild-type FAK (FAK-WT) at comparable levels to endogenous
FAK in both CD-1 nude and FVB (syngeneic) host mouse strains.
In CD-1 nude mice, SCC FAK/ tumor growth was character-
ized by amodest growth delay (Figure 1A) as reported previously
(Serrels et al., 2012). By contrast, in FVB mice, SCC FAK/ tu-
mor growthwas characterized by an initial period of growth in the
first 7 days followed by complete regression by day 21 (Fig-
ure 1B). Thus, FAK expression is required for the survival andCell 163, 160–173, Segrowth of SCC tumors in FVB mice with
a functional adaptive immune system.
SCC FAK/ Tumor Regression Is
Dependent on CD8+ T Cells
To characterize the role of adaptive im-
munity in FAK/ SCC tumor regression,
we used antibody-mediated T cell deple-
tion in animals bearing FAK/ tumors
(Figures 1C and S1). Depletion of CD4+ T cells had no effect on
tumor growth. In contrast, depletion of CD8+ T cells, either alone
or in combination with CD4+ T cells, restored SCC FAK/ tumor
growth. This implies that cytotoxic CD8+ T cells were respon-
sible for regression of FAK/ tumors (Figure 1C) but does not
exclude an accessory role for CD4+ T cells. T cell depletion in
mice bearing SCC FAK-WT tumors (Figure 1D) revealed that:
(1) depletion of CD8+ T cells, either alone or in combination
with CD4+ T cells, caused a significant increase in tumor growth
when compared to isotype-treated controls at day 14, and
(2) depletion of CD4+ T cells alone caused regression of FAK-
WT SCC tumors by day 21. This implied that FAK-expressing
tumors were also under negative pressure from the immune sys-
tem and that cells from the CD4+ T cell compartment play a role
in protecting FAK-WT tumors from immune-mediated regression
(reason discussed later; Figure 3).
Next, we re-challenged mice with 1 3 106 SCC FAK-WT cells
after regression of primary FAK/ SCC tumors, following 7 days
of tumor-free survival after the tumors had regressed (Figure 1E,
top andmiddle graphs). Neither FAK-deficient nor FAK-express-
ing SCC cells were able to grow after the mice had been pre-
challenged with SCC FAK/ cells. As controls, SCC FAK-WT
and FAK/ cells were injected at day 28 into mice with no
pre-challenge, and these grew as expected (Figure 1E, bottom).ptember 24, 2015 ª2015 The Authors 161
This implies that, following FAK/ SCC tumor regression, host
mice remain immunized against further tumor challenge
because immunological memory had been established. It is
possible that either broad immunization against SCCs may
have occurred or, more likely, that the FAK/ and FAK-WT
SCCs shared common antigen(s) that are expressed irrespec-
tive of FAK status. We conclude that FAK enables SCC cancer
cells to suppress an adaptive immune response rather than to
circumvent it through evading recognition per se. SCC FAK/
cells in which a FAK kinase-deficient mutant was re-expressed
(SCC FAK-KD) initially grew and then regressed with kinetics
that were only modestly delayed when compared to FAK/
cells, indicating that immune suppression depends on FAK ki-
nase activity (Figure 1F).
We next investigated the nature of the T cell response within
tumors derived from all three SCC cell lines using FACS analysis
on disaggregated tumor tissue taken at day 7. We did not
observe a significant change in the percentage of total CD4+
T cells (Figures 2A and S2 and Table S2) or the percentage of
CD4+ T cells that expressed the activation marker CD69 (Fig-
ure 2B). In contrast, we did observe a significant increase in
the proportion of effector CD4+CD44hiCD62Llow T cells in SCC
FAK/ and FAK-KD tumors when compared to FAK-WT tumors
(Figures 2C and S2 and Table S2). Analysis of tumor-infiltrating
CD8+ T cells revealed a significant increase in SCC FAK/
and SCC FAK-KD tumors when compared to SCC FAK-WT tu-
mors (Figures 2D and S2 and Table S2), indicative of a height-
ened cytotoxic anti-tumor immune response. Staining with the
activation marker CD69 identified the presence of CD8+CD69+
T cells in all tumors (Figure 2E). Further analysis revealed an in-
crease in percentage of effector CD8+CD44hiCD62Llow T cells
in SCC FAK/ and SCC FAK-KD tumors when compared to
SCC FAK-WT tumors (Figures 2F and S2 and Table S2), espe-
cially when effector CD8+ T cell numbers were normalized to
account for the observed changes in total CD8+ T cells and pre-
sented as a ‘‘fold change’’ (Figure 2G). However, while SCC
FAK/ and SCC FAK-KD tumors had increased effector CD8+
T cells, there were activated CD8+ T cells present in all of the
SCC tumors, raising the question of why SCC FAK-WT tumors
do not succumb to the cytotoxic CD8+ T cell response.
It is now established that not only the quantity of tumor-infil-
trating CD8+ T cells is important, but also their ‘‘quality.’’
Tumor-induced T cell exhaustion has been reported in a number
of tumor types, including melanoma (Fourcade et al., 2010) and
ovarian cancer (Matsuzaki et al., 2010), and is characterized by
expression of co-inhibitory surface receptors, including pro-
grammed death receptor 1 (PD-1), lymphocyte-activation gene
3 (LAG-3), and T cell immunoglobulin mucin-3 (Tim-3), either
alone or in combination (Fourcade et al., 2010; Sakuishi et al.,
2010; Wherry, 2011). Analysis of these markers on antigen-
primed CD8+CD44hi T cells infiltrating SCC FAK-WT, FAK/,
and FAK-KD tumors revealed increased surface expression of
PD-1, LAG-3, and Tim-3 in CD8+CD44hi T cells present in SCC
FAK-WT tumors (Figures 2H–2J). Together, our data imply that
antigen-primed CD8+CD44hi T cells infiltrating SCC FAK-WT tu-
mors exhibit a heightened state of exhaustion indicative of a
dysfunctional T cell response. Linked to their exhausted state,
there was also evidence of decreased proliferation of CD8+162 Cell 163, 160–173, September 24, 2015 ª2015 The AuthorsT cells isolated from SCC FAK-WT tumors (judged by Ki-67
staining in Figure 2K).
Histological staining of tumor sections taken at day 7 revealed
that: (1) CD8+ T cells are present throughout all tumors, and
(2) while CD8+ T cells infiltrating SCC FAK-WT tumors appear
predominantly as individual cells, CD8+ T cells infiltrating SCC
FAK/ and FAK-KD tumors are clustered (Figure 2L). Thus,
the ability of SCC FAK-WT tumors to evade the anti-tumor im-
mune response is not due to limited CD8+ T cell penetration
into these tumors.
FAK Expression Drives Establishment
of an Immuno-Suppressive Environment
Macrophages, myeloid-derived suppressor cells (MDSC), and
Tregs with intrinsic immuno-suppressive capabilities can pro-
mote tumor development by inhibiting cytotoxic CD8+ T cell ac-
tivity in mouse and humans (Beyer and Schultze, 2006; Biragyn
and Longo, 2012; Marigo et al., 2008). Flow cytometric analysis
revealed no differences in macrophage or MDSC populations
that correlated with tumor regression (Figures 3A, 3B, S3, and
S4 and Table S2), although this does not rule out an accessory
role for these cells in eventual tumor clearance. However, we
did find a significantly greater number of CD4+FoxP3+CD25+
Tregs in SCC FAK-WT tumors (Figures 3C and S4 and Table
S2) when compared with FAK/ and FAK-KD tumors (Fig-
ure 3C). Tregs have been associated with the development of
CD8+ T cell exhaustion (Sakuishi et al., 2013) and may therefore
be linked to the CD8+ T cell exhaustion that we observed in SCC
FAK-WT tumors (Figures 2H–2J). We next calculated the ratio of
CD8+ T cells to Tregs (Figure 3D), as this has been reported to
correlate with poor prognosis in a number of tumor types (Sato
et al., 2005; Shah et al., 2011). We found a substantially lower
CD8+ T cell to Treg ratio in SCC FAK-WT tumors when compared
to SCC FAK/ and SCC FAK-KD tumors, which correlated with
outcome in terms of tumor tolerance versus immune-mediated
tumor regression.
Tregs Protect FAK-WT Tumors from Immune-Mediated
Regression
We next examined SCC FAK-WT tumor growth in animals
treated with an anti-CD25 antibody to deplete Tregs (Figure 3E).
Depletion of CD25+ cells led to regression of SCC FAK-WT
tumors. Therefore, FAK-dependent Tregs are required for the
growth of FAK-WT-expressing tumors by creating an im-
muno-suppressive environment that impairs cytotoxic CD8+
T cell activity. This role of CD4+ Tregs is the likely reason for ef-
fects of the CD4-depleting antibody in promoting regression of
SCC FAK-WT tumors (Figure 1D). We note that high Treg levels
have been reported in a number of solid tumor types (Beyer
and Schultze, 2006) and that elevated Tregs are linked to
poor clinical outcome (Beyer and Schultze, 2006; Sato et al.,
2005).
We demonstrated that Tregs derived from SCC FAK-WT tu-
mors expressed the transcription factor (TF) Helios (Figure S5A),
indicative of thymic origin (Thornton et al., 2010). Thus, we hy-
pothesized that FAK may drive the recruitment and expansion
of the intra-tumoral Tregs by influencing the availability of
secreted factors.
Figure 2. FAK-Depleted Tumors Exhibit a Heightened CD8+ T Cell Response
(A) FACS quantification of total intra-tumoral CD4+ T cells.
(B) FACS quantification of CD69+ cells as a percentage of CD4+ T cells.
(C) FACS quantification of CD4+CD44hiCD62Llow, CD4+CD44hiCD62Lhi, CD4+CD44lowCD62Llow T cell subpopulations.
(D) FACS quantification of total intra-tumoral CD8+ T cells.
(E) FACS quantification of CD69+ cells as a percentage of CD8+ T cells.
(F) Quantification of CD8+CD44hiCD62Llow, CD8+CD44hiCD62Lhi, CD8+CD44lowCD62Llow T cell subpopulations.
(G) Changes in effector (CD8+CD44hiCD62Llow) CD8+ T cells normalized to total CD8+ T cell proportions.
(H) FACS quantification of PD-1+LAG-3+ T cells as a percentage of CD8+CD44hi tumor-infiltrating T cells. n = 6 tumors.
(I) FACS quantification of PD-1+Tim-3+ T cells as a percentage of CD8+CD44hi tumor-infiltrating T cells. n = 3 tumors.
(J) FACS quantification of PD-1+Tim-3+LAG-3+ T cells as a percentage of CD8+CD44hi tumor-infiltrating T cells. n = 3 tumors.
(K) FACS quantification of Ki-67+ cells as a percentage of tumor-infiltrating CD8+ T cells. n = 3 tumors.
(L) Representative histological staining of CD8 in frozen sections from SCC FAK-WT, SCC FAK/, and SCC FAK-KD tumors. Dashed white lines demark tumor
boundary.
Scale bars, 500 mm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant; Tukey-corrected one-way ANOVA (C and F, CD44hiCD62Llow only). Data
are represented as mean ± SEM; n = 5 tumors unless stated.FAK Regulates the Transcription of Chemokines and
Cytokines to Control Tregs
To address how FAK activity in SCC cancer cells promotes
elevated intra-tumoral Tregs, we next analyzed global transcrip-tional profiles of SCC FAK-WT and SCC FAK/ cells using Affy-
metrix GeneChip microarrays (Figure 4A). FAK expression re-
sulted in the upregulation of 498 genes and the downregulation
of 598 genes (p < 0.01). The upregulated transcript set in SCCCell 163, 160–173, September 24, 2015 ª2015 The Authors 163
Figure 3. FAK Regulates the Immuno-Sup-
pressive Microenvironment
(A) FACS quantification of Ly6Chi and Ly6Clow
macrophage populations expressed as a per-
centage of tumor-infiltrating CD45+ leukocytes.
(B) FACS quantification of Ly6ChiGr1low (M-MDSC)
and Ly6CintGr1hi (G-MDSC) populations ex-
pressed as a percentage of tumor-infiltrating
CD45+ leukocytes.
(C) Quantification of CD4+CD25+FoxP3+ Tregs
expressed as a percentage of tumor-infiltrating
CD4+ T cells.
(D) CD8+ T cell-to-Treg ratio calculated using
mean values from Figures 2D and 3C.
(E) SCC FAK-WT tumor growth in FVB mice
treated with anti-CD25 depleting antibody.
n = 6 tumors. * or +p < 0.05, ++p < 0.01, ***p <
0.001, **** or ++++p < 0.0001; Tukey-corrected
one-way ANOVA (A, *, Ly6Chi; +, Ly6Clow). Data are
represented as mean ± SEM; n = 5 tumors unless
stated.FAK-WT cells was associated with a number of processes,
including cell migration, receptor binding, secretion, wounding,
and ovulation (Figure 4B, top). Analysis of this gene set revealed
the chemokine ligand group of genes to be significantly overrep-
resented (Figure 4B, bottom), which is interesting given that a
number of these chemokines and cytokines mediate both Treg
recruitment to tumors and induction of peripheral Tregs within
tumors (Goldstein et al., 2013; Ondondo et al., 2013).
To establish which chemokines and cytokines were regulated
by FAK and to address whether the FAK-dependent transcrip-
tional profile was linked to chemokine receptor expression on tu-
mor-infiltrating Tregs, we performed quantitative (q)RT-PCR
array analysis. Comparison of chemokine/cytokine transcript
levels between SCC FAK-WT and SCC FAK/ cells revealed a
subset of ligands increased >2-fold in SCC FAK-WT cells (Fig-
ure 4C). Several of these (Ccl1, Ccl5, Ccl7, Cxcl10) have roles
in Treg recruitment (Ondondo et al., 2013) (green arrowheads,
Figure 4C), while one (Tgfb2) has a reported role in peripheral in-
duction and expansion of Tregs (Goldstein et al., 2013) (red
arrowhead, Figure 4C). To complement this, comparison of
Tregs isolated from the thymus of normal FVB mice with those
isolated directly from SCC FAK-WT tumors revealed a chemo-
kine receptor switch (Figure 4D). We found increased expression
of the cognate receptors for five of the six chemokine ligands up-
regulated in SCC FAK-WT cells (Figure 4C). These receptor
changes may represent a switch from lymphoid homing recep-
tors, including Ccr7 and Cxcr4, toward expression of memory/
effector-type chemokine receptors, including Ccr2, Ccr5, Ccr8,
and Cxcr6, involved in recruitment to non-lymphoid tissues
and sites of inflammation. Network analysis of the relationship
between FAK-dependent chemokine ligand expression in SCC
cells and tumor-infiltrating Treg chemokine receptor expression
revealed the existence of a FAK-dependent paracrine signaling
axis between cancer cells and intra-tumoral Tregs based on che-164 Cell 163, 160–173, September 24, 2015 ª2015 The Authorsmokine ligand-receptor interactions (Figure 4E). Furthermore, (q)
RT-PCR analysis of Ccl5, Cxcl10, and Tgfb2 demonstrated that
their expression was dependent on FAK kinase activity (Fig-
ure 4F). We note that disruption of the Ccl5/Ccr5 axis in a model
of pancreatic adenocarcinoma results in reduced intra-tumoral
Tregs and slows tumor growth (Tan et al., 2009), implying that
FAK-dependent regulation of this paracrine signaling axis may
be more generally important. Thus, FAK activity regulates the
expression of a subset of chemokines that can specifically
mediate crosstalk between tumor cells and tumor-infiltrating
Tregs. This likely has importance in recruitment and retention
of CD4+FoxP3+CD25+ Tregs into SCC FAK-WT tumors.
Nuclear FAK Regulates the Transcription of Ccl5
and TGFb2 to Increase Tregs
The finding that the Tregs enriched in SCC FAK-WT tumors
were likely recruited into SCC FAK-WT tumors led us to
consider a potential role for Ccl5 that has been implicated in
the recruitment and expansion of CD4+FoxP3+CD25+ Tregs
(Tan et al., 2009), via the paracrine signaling axis that we iden-
tified. We found that efficient knockdown of Ccl5 using two
independent shRNA hairpins (P1 and P2, Figure 5A) resulted
in SCC FAK-WT shRNA-Ccl5 tumor regression by days 21–27
(Figure 5B). We measured the absolute number of Tregs in
SCC FAK-WT shRNA-Ccl5 tumors at day 7 and found that there
was a substantial reduction in both Ccl5-depleted tumors when
compared with empty vector control SCC FAK-WT pLKO tu-
mors (Figure 5C).
Expanding on these findings, shRNA-mediated knockdown of
Tgfb2 expression in SCC FAK-WT cells also influenced tumor
growth (Figures S5B and S5C). Partial knockdown of TGFb2
had complex effects, which resulted in one of two outcomes.
One group (Figure S5C, dashed blue line), grew more rapidly
and ulcerated, leading to removal from study at day 14. In the
Figure 4. FAK Regulates Transcription of Cytokines Implicated in Treg Recruitment and Expansion
(A) Transcriptomic profiling of SCC FAK-WT and SCC FAK/ cells.
(B) Functional enrichment analysis of genes upregulated in SCC FAK-WT cells (bottom gray bar in A). Overrepresented biological processes are displayed as a
heatmap (log10-transformed color scale) (top); asterisks indicate presence of cytokine-related genes. Overrepresented gene families are displayed as a bar chart
(bottom). p < 0.05; Benjamini–Hochberg-corrected hypergeometric tests.
(C) qRT-PCR array analysis of cytokine and chemokine expression in SCCFAK-WT andSCC FAK/ cells. Gray bar indicates cluster of genes upregulated in SCC
FAK-WT cells; cytokine and chemokine gene names are listed. Green arrowheads indicate reported roles in Treg recruitment; red arrowhead indicates reported
role in peripheral Treg induction.
(D) qRT-PCR array analysis of chemokine and receptor expression in tumor- and thymus-derived Tregs. Gray bar indicates cluster of genes upregulated in tumor-
derived Tregs; receptor gene names are listed.
(E) Interaction network analysis of chemokine ligand gene expression detected in SCC cells (circles, left) and corresponding receptor gene expression detected in
Tregs (squares, right). Genes are ordered vertically by fold change. Light gray lines connect receptor-ligand pairs; green lines indicate pairs upregulated at least
2-fold in SCC FAK-WT cells and tumor-derived Tregs.
(F) qRT-PCR analysis of selected cytokine and chemokine gene expression in SCC cells. ***p < 0.001, ****p < 0.0001; Tukey-corrected one-way ANOVA. Data are
represented as mean ± SEM.
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Figure 5. Nuclear FAK Regulates Transcription of Ccl5, which Is Required for Treg Recruitment and Tumor Growth
(A) qRT-PCR analysis of Ccl5 gene expression knockdown in SCC FAK-WT cells stably expressing two independent shRNA constructs targeting Ccl5 (P1
and P2).
(B) SCC FAK-WT shRNA-Ccl5 tumor growth in FVB mice. n = 6 tumors.
(C) FACS quantitation of tumor-infiltrating Treg numbers from SCC FAK-WT shRNA-Ccl5 tumors. Data represent a single value from six pooled tumors.
(D) Western blotting of cytoplasmic, nuclear, and total protein fractions from SCC FAK-WT, SCC FAK/, and SCC FAK-NLS cells.
(E) qRT-PCR analysis of Ccl5 gene expression in SCC FAK-NLS cells.
(F) Tumor growth of SCC FAK-NLS cells in FVB mice.
(G) Western blotting of cytoplasmic, nuclear, and total protein fractions from SCC FAK-WT, SCC FAK/, and SCC FAK-KD cells.
(H) Western blotting of whole-cell (WC) and nuclear (Nuc) protein fractions from SCC FAK-WT cells and primary skin keratinocytes. 60 s exposure time is shown
for all samples; additional 10 min exposure time is shown for FAK in keratinocyte samples. GAPDH, cytoplasmic; PARP, nuclear.
***p < 0.001, ****p < 0.0001; Tukey-corrected one-way ANOVA. Data are represented as mean ± SEM unless stated.other group that did not display such frank ulceration, we
observed tumor regression by day 27 (Figure S5C, dashed red
line). Analysis of Treg levels in SCC FAK-WT shRNA-TGFb2 tu-
mors at day 7 (regardless of initial growth characteristics) re-
vealed that TGFb2 knockdown was also associated with a
reduction in CD4+FoxP3+CD25+ Tregs (Figure S5D). Therefore,166 Cell 163, 160–173, September 24, 2015 ª2015 The Authorswhile the effects of reducing TGFb2 expression aremore compli-
cated than for Ccl5, FAK-dependent TGFb2 expression does
contribute to elevated CD4+FoxP3+CD25+ Tregs in SCC FAK-
WT tumors; and in the subset of mice bearing tumors that
were able to complete the study, TGFb2 knockdown also caused
tumor regression.
Our findings that FAK regulated the transcription of cytokines
and chemokines (including Ccl5 and TGFb2) that were associ-
ated with elevated intra-tumoral Tregs and tumor tolerance led
us to consider a possible role for nuclear FAK in regulating the
transcription of these genes. Based on previous reports (Lim
et al., 2008), which identified putative NLSs within the FERM
domain of FAK, we constructed an optimally nuclear targeting-
impaired mutant FAK by replacing two arginines (positions 177
and 178) and four lysines (positions 190, 191, 216, and 218)
with alanines (termed FAK-NLS). Western blotting of cyto-
plasmic and nuclear fractions confirmed that the FAK-NLS
mutant was indeed defective in nuclear localization (Figure 5D).
Subsequent (q)RT-PCR analysis of Ccl5 and Tgfb2 expression
in SCC cells expressing only FAK-NLS revealed that FAK nuclear
localization was required for transcription of these genes (Fig-
ures 5E and S5E, respectively). Thus, nuclear FAK drives the
transcription of Ccl5 and TGFb2, which are required for recruit-
ment and expansion of immuno-suppressive Tregs into SCC tu-
mors, altering the balance between CD8+ T cells and Tregs in
favor of tumor tolerance. In support of this, growth of SCC
FAK-NLS tumor cells was similar to that of SCC FAK/, with ul-
timate tumor regression (Figure 5F). This confirmed that it was
nuclear FAK that afforded protection from the anti-tumor im-
mune response. Western blotting of cytoplasmic and nuclear
fractions from SCC FAK-KD showed that the kinase-deficient
mutant was able to localize to the nucleus, so we conclude
that the immune modulatory effects of FAK are dependent on
FAK kinase activity in the nucleus (Figure 5G).
We next examined nuclear FAK levels in primary skin keratino-
cytes, the normal cellular counterparts of the SCC cells used
here, and did not find detectable nuclear FAK (Figure 5H).
Thus, abundant nuclear localization, and therefore the capacity
to exert regulatory control over chemokine and cytokine expres-
sion, is likely a feature of oncogenic transformation in skin kera-
tinocytes. This suggests that the nuclear functions of FAK that
we have identified—namely, regulating transcription of chemo-
kine/cytokine networks—may be associated with the cancerous
state when FAK is highly expressed.
Nuclear FAK Interacts with a Network of Ccl5
Transcriptional Regulators
Having established an important role for the nuclear FAK-
dependent transcription of Ccl5 in mediating recruitment and
expansion of intra-tumoral Tregs, we wanted to determine
how nuclear FAK could exert control over Ccl5 transcription.
Using sucrose gradients, we fractionated the nuclei of SCC
FAK-WT cells and demonstrated that nuclear FAK was present
in the chromatin-containing fraction (Figure 6A). Transcriptional
regulation of Ccl5 is mediated predominantly through six short
regulatory elements contained within a region of the Ccl5 pro-
moter spanning 300 base pairs (Fessele et al., 2002). These
regulatory elements contain binding sites for a number of
TFs, including AP-1, C/EBP, IRF-1, NF-kB, and TATA box-bind-
ing protein (TBP), which is part of the transcription factor IID
complex (TFIID). Using FAK immunoprecipitation and quantita-
tive label-free mass spectrometry, we identified FAK binding
partners in purified nuclear extracts and contextualized these
by mapping onto a network of proteins associated with pre-dicted Ccl5 TFs (constructed in silico; Figure 6B). This integra-
tive approach identified a subset of Ccl5 TFs and regulators of
these that interact with FAK in SCC cell nuclei (Figures 6C, S6
and Table S1). Interaction network analysis of this protein sub-
set revealed nuclear FAK binding partners with roles in multiple
transcriptional pathways, including regulators of AP-1, C/EBP,
IRF-1/-7, NF-kB/Rel, and TFIID. Thus, we identified nuclear
FAK binding partners that can interact, directly or indirectly,
with five of the six main regulatory elements reported to control
transcription of Ccl5 in multiple cell types (Fessele et al., 2002).
Given that our interaction network was somewhat dominated
by proteins associated with the TFIID pathway, including three
TBP-associated factors (TAFs) (Figures 6C and S6), we used
co-immunoprecipitation to confirm the interaction of nuclear
FAK with one of these, TAF9, a core component of the TFIID
complex (D’Alessio et al., 2009) (Figure 6D). Our data show
that FAK binds to core components of the transcriptional ma-
chinery, many of which are known to be located on the pro-
moter of genes undergoing active transcription and that are
known or predicted to regulate Ccl5. Therefore, in SCC cells,
nuclear FAK associates with chromatin and is physically linked
to a network of TFs and their regulators known to modulate
Ccl5 expression.
Small-Molecule FAK Kinase Inhibitor Promotes
Immune-Mediated Tumor Clearance
Therapeutic targeting of FAK kinase activity using small-mole-
cule inhibitors will inhibit FAK signaling not only in tumor cells,
but also potentially in multiple host cell types. To complement
expression of the FAK-KD mutant protein in the cancer cells
and investigate whether a FAK inhibitor could induce immune-
mediated regression of SCC tumors, we used the FAK/Pyk2 ki-
nase inhibitor VS-4718 (Shapiro et al., 2014), which is currently
in clinical development. Mice were treated with VS-4718 at
75 mg/kg for 24 hr prior to injection of 1 3 106 FAK-WT or
FAK/ SCC tumor cells and twice daily thereafter. This resulted
in VS-4718-induced regression of SCC FAK-WT tumors by day
24 (Figure 7A). Following cessation of VS-4718 treatment, no
tumor regrowth was observed (data not shown). SCC FAK/ tu-
mor growth and clearance was not greatly affected by VS-4718
treatment, suggesting that the anti-tumor effects of VS-4718 can
be explained by FAK inhibition in tumor cells. Activity of VS-4718
was confirmed using an ELISA to measure FAK autophosphory-
lation on tyrosine-397 in tumor lysates from mice treated with
75 mg/kg VS-4718 (Figure S7). Regression of VS-4718-treated
SCC tumors was not accompanied by loss of cell viability at
day 7, as measured by FACS using a viability stain following tu-
mor disaggregation (Figure 7B). There was a significant but small
increase in leukocytes in VS-4718-treated SCC FAK-WT tumors
(Figure 7C) and a significant increase in total CD4+ T cells (Fig-
ures 7D andS2 and Table S2) and effector CD4+CD44hiCD62Llow
T cells (Figures 7E and S2 and Table S2). A significant increase in
CD8+ T cells was also evident in SCC FAK-WT VS-4718-treated
tumors (Figures 7F and S2 and Table S2), although there was no
change in effector CD8+CD44hiCD62Llow T cells (Figures 7G and
S2 and Table S2). Crucially, there was a significant reduction in
CD4+CD25+FoxP3+ Treg cells in VS-4718-treated SCC FAK-
WT tumors, which was similar to that observed in vehicle andCell 163, 160–173, September 24, 2015 ª2015 The Authors 167
Figure 6. Nuclear FAK Interacts with Regulators of Ccl5 Transcription
(A) Sucrose fractionation of soluble chromatin prepared from SCC FAK-WT cell nuclei. Protein preparations recovered from each fraction were analyzed by
western blotting (top). DNA recovered from each fraction was analyzed by agarose gel electrophoresis (bottom, 1 kilobase [kb] and 100 base pair [bp] ladders
shown). Fraction 7 (black arrowhead) represents the chromatin-containing fraction.
(B) Schematic detailing the workflow used for proteomic analysis of the nuclear FAK interactome in the context of Ccl5 transcription factors (TFs).
(C) Interaction network analysis of proteins that bind FAK in the nucleus of SCC cells. PredictedCcl5 TFs (squares, bottom) and respective TF binders (circles, top)
enriched by at least 4-fold in nuclear FAK immunoprecipitations (SCC FAK-WT over SCC FAK/ controls; p < 0.05) are shown (stringent network). Ccl5 TFs not
detected (ND) are shown as gray squares. TF complexes or groups are indicated; proteins are labeledwith gene names for clarity. TF binders are aligned above TF
groups with which there are the greatest number of reported interactions. For full network, see Figure S6; for protein interaction list, see Table S1.
(D) Isolation of the TFIID component TAF9 by FAK immunoprecipitation (IP) from SCC FAK-WT cell nuclear extracts.VS-4718-treated SCC FAK/ tumors (Figures 7H and S4 and
Table S2).
Thus, VS-4718 promoted robust anti-tumor activity, with
similar immune cell changes to that observed upon FAK deletion
or expression of a kinase-deficient form of FAK. Furthermore,
anti-tumor efficacy of VS-4718 was also dependent on CD8+
T cells, and SCC FAK-WT tumors treated with VS-4718 on a
CD8+ T cell-depleted background exhibited a growth delay but168 Cell 163, 160–173, September 24, 2015 ª2015 The Authorsdid not undergo tumor regression (Figure 7I). We conclude that
the FAK kinase inhibitor targets mechanisms of immune
suppression andmay therefore represent a form of effective ‘‘im-
muno-modulatory’’ therapy that reduces Tregs in the tumor envi-
ronment. Importantly, the FAK kinase inhibitor does not affect
the cytotoxic function of antigen-primed CD8+ T cells. We also
found that VS-4718 treatment that was initiated 5 days post-
inoculation of 1 3 106 SCC FAK-WT cells, when these had
Figure 7. The FAK Kinase Inhibitor VS-4718 Leads to Immune-Mediated SCC Clearance
(A) SCC FAK-WT and SCC FAK/ tumor growth in FVB mice treated with either vehicle or VS-4718. Treatment started 24 hr pre-tumor cell inoculation and
continued for the duration of the experiment.
(B) FACS analysis of cell viability from disaggregated tumors treated with either vehicle or VS-4718.
(C) FACS analysis of vehicle- or VS-4718-treated tumor-infiltrating leukocytes expressed as a percentage of viable CD45+ cells relative to the total number of
single cells.
(D) FACS analysis of tumor-infiltrating CD4+ T cells from vehicle- or VS-4718-treated tumors.
(E) FACS sub-categorization of tumor-infiltrating CD4+ T cells into CD45+CD3+CD4+CD8CD44hiCD62Llow, CD45+CD3+CD4+CD8CD44hiCD62Lhi, and
CD45+CD3+CD4+CD8CD44lowCD62Llow populations.
(F) FACS analysis of tumor-infiltrating CD8+ T cells from vehicle- or VS-4718-treated tumors.
(G) FACS sub-categorization of tumor-infiltrating CD8+ T cells into CD45+CD3+CD4CD8+CD44hiCD62Llow, CD45+CD3+CD4CD8+CD44hiCD62Lhi, and
CD45+CD3+CD4CD8+CD44lowCD62Llow populations.
(H) FACS analysis of tumor-infiltrating CD4+CD25+FoxP3+ Tregs expressed as a percentage of tumor-infiltrating CD4+ T cells.
(I) SCC FAK-WT tumor growth in FVB mice treated with either vehicle or VS-4718 and either isotype control or CD8-depleting antibodies.
(J) SCC FAK-WT and SCC FAK/ tumor growth in FVB mice treated with either vehicle or VS-4718. Treatment started 5 days post-tumor cell inoculation (gray
dashed line) and continued for the duration of the experiment.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant; Tukey-corrected one-way ANOVA (E and G, CD44hiCD62Llow only). Data are represented as
mean ± SEM; n = 6 tumors.
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already formed palpable tumors of50mm3, led to complete tu-
mor regression (Figure 7J).
DISCUSSION
We show that nuclear FAK in SCC cancer cells drives the tran-
scription of chemokines and cytokines, including Ccl5 and
TGFb2, which promote the formation of an immuno-suppressive,
pro-tumorigenic microenvironment. This is dependent on FAK
kinase activity, and expression of a catalytically inactive mutant
FAK protein (FAK-KD) or treatment with a small-molecule inhib-
itor causes tumor regression. This is effective even when tumors
are already established, raising the exciting possibility that tar-
geting of FAK kinase activity may have immune-mediated anti-
tumor efficacy in patients. We established that nuclear FAK is
associated with chromatin and interacts with a number of TFs
and transcriptional regulators, including components of the
TFIID complex, that are linked to regulation of Ccl5 expression.
Our data imply that FAK interacts with core transcriptional
machinery to influence gene transcription and promote tumor
immune escape.
Historically, FAK has been recognized as an adhesion-related
non-receptor protein tyrosine kinase that clusters at focal adhe-
sion (FA) structures and regulates cancer-associated processes,
including adhesion, migration, invasion, survival, and prolifera-
tion (reviewed in Frame et al., 2010). FAK was also found to
translocate to the nucleus (Lim et al., 2008; Luo et al., 2009b),
leading to the idea of nuclear functions for FAK within the nu-
cleus. Our data show that, at least in cancer cells, FAK regulates
inflammatory transcriptional programs associated with genera-
tion and maintenance of a pro-tumorigenic and immuno-sup-
pressive microenvironment. FAK associates with chromatin,
and in the context of Ccl5 expression, it interacts with a number
of TFs, and regulators of TFs, that bind regulatory elements in the
Ccl5 promoter (Fessele et al., 2002). Our data imply that FAK ex-
ists in complexes with a number of TAF proteins, including TAF9
and TAF12, key components of the core promoter complex
TFIID that serves to initiate transcription by driving recruitment
of chromatin remodeling complexes, coactivators, and RNA po-
lymerase II to the promoter (D’Alessio et al., 2009). Therefore,
FAK interacts with components of the core transcriptional
machinery in order to drive transcription of chemokines and cy-
tokines that contribute to recruitment of Tregs into the tumor
environment, promoting immunological tolerance and permitting
tumor growth.
Recently, nuclear accumulation of active FAK (phosphory-
lated on Tyr-397) within tumor cells of patients with colorectal
cancer was reported to correlate with poor prognosis (Albasri
et al., 2014), highlighting the need to understand the nature of
FAK’s role within the nucleus. Studies using endothelial cells,
muscle cells, and fibroblasts have previously reported low
steady-state levels of nuclear FAK that are substantially
increased in response to cellular stress (Lim, 2013; Lim et al.,
2008; Luo et al., 2009b). Our work implies that oncogenic stress
is another route to inducing high levels of nuclear FAK and that
this, in turn, can influence transcriptional programs, such as the
chemokine and cytokine networks that control the tumor
microenvironment.170 Cell 163, 160–173, September 24, 2015 ª2015 The AuthorsA number of therapeutic strategies targeting components of
the immuno-suppressive tumor microenvironment are currently
being tested, with the aim of restoring anti-tumor immunity by
releasing the break on CD8+ T cell cytotoxic activity. In pre-clin-
ical models of cancer, targeting Tregs (Ali et al., 2014; Bos et al.,
2013) has shown anti-tumor efficacy, either alone or when used
in combination with agents that enhance CD8+ T cell activation.
A clinical study combining agents targeting cytotoxic-T-lympho-
cyte-associated antigen 4 (CTLA-4), which is thought to influ-
ence Treg function (Peggs et al., 2009; Quezada et al., 2006;
Simpson et al., 2013; Wing et al., 2008), and PD-1, which blocks
signals that inhibit T cell function, has reported impressive re-
sponses in patients with advanced melanoma (Wolchok et al.,
2013). However, this combination of checkpoint blockade anti-
bodies elicits substantial side effects in >50% of patients, high-
lighting the need to find alternative combinations with improved
tolerability. We have shown that targeting FAK kinase activity has
the potential to modulate intra-tumoral Treg levels, resulting in
robust CD8+ T cell anti-tumor immunity, while others have re-
ported previously that FAK kinase inhibitors block monocyte/
macrophage and cancer-associated fibroblast recruitment into
tumors by virtue of FAK’s role in regulating their migration
(Stokes et al., 2011). Taken together, these findings suggest
that targeting the pleiotropic cellular functions of FAK may
have a broad impact on the immuno-suppressive tumor micro-
environment, differentiating these agents frommany therapeutic
approaches that target single immune cell populations.
Targeting a molecular pathway that is upregulated in cancer
cells may provide tumor specificity and help to overcome
some of the potential issues with severe autoimmunity when
modulating immune cell populations. FAK inhibitors, such as
VS-4718, are in clinical development. VS-4718 is currently in a
phase I dose escalation clinical trial in patients with solid tumors
(www.clinicaltrials.gov NCT01849744). Our findings provide
good rationale for pre-clinical and clinical testing of FAK kinase
inhibitors alongside agents that stimulate CD8+ T cell activity,
such as the checkpoint blockade therapies that target PD-1
and CTLA-4, which are both in clinical development (Pardoll,
2012).
EXPERIMENTAL PROCEDURES
Experiments involving animals were carried out in accordance with the
UKCCCR guidelines by approved protocol (HO PL 60/4248). Brief experi-
mental procedures are listed here. For details, please see the Supplemental
Experimental Procedures.
Generation of FAK Nuclear Localization Mutant
Mutations were introduced into FAK-WT at R177A, R178A, K190A, K191A,
K216A, and K218A using PCR-based site-directed mutagenesis.
Cell Lines
Isolation and generation of the FAKSCC cell model is described in Serrels et al.
(2012). Keratinocyte cultureswere prepared as detailed inMcLean et al. (2004).
Western Blot Analysis
To prepare whole-cell lysates, cells were washed in cold PBS and lysed in
RIPA buffer. Cytoplasmic and nuclear extracts were prepared as described
in Lim et al. (2008). Lysates were resolved by gel electrophoresis, transferred
to nitrocellulose, and probed with respective antibodies.
Subcutaneous Tumor Growth
Cells were injected into both flanks of either CD-1 nude mice or FVB mice and
tumor growth measured twice-weekly. Animals were sacrificed when tumors
reached maximum allowed size or when signs of ulceration were evident.
For treatment with VS-4718, drug was prepared in 0.5% carboxymethyl cellu-
lose + 0.1% Tween 80 and mice treated at 75 mg/kg BID by gavage. No signs
of toxicity were observed.
Tumor Growth following Re-Challenge
SCC FAK/ cells were injected into the left flank of FVBmice. Following tumor
regression, mice were left for 7 days before being challenged with SCC FAK-
WT or FAK/ cells injected into the right flank. Tumor growth was measured
twice-weekly. Control groups were injected into both flanks at day 28 using
mice that had not been pre-challenged with SCC FAK/ cells.
CD4+, CD8+, and CD25+ T Cell Depletion
T cell depletion was achieved following IP injection of 150 mg of depleting anti-
body into female age-matched FVB mice for 3 consecutive days and was
maintained by further IP injection at 3 day intervals until the study was termi-
nated. SCC FAK-WT or FAK/ cells were injected into both flanks 6 days after
initial antibody treatment and tumor growth measured. The extent of T cell
depletion was determined at the end of the study using FACS (Figure S1).
FACS Analysis of Immune Cell Populations
Tumors established following injection of SCC cells into both flanks of an FVB
mouse were removed at day 7. Tumor tissue was processed to obtain single
cell suspension for staining and subsequent FACS analysis (antibodies listed
in Table S2).
Gene Expression Profiling
RNA was analyzed using the GeneChip Mouse Genome 430 2.0 Array.
Normalized data for differentially expressed genes were median centered
and clustered using Cluster 3.0 and Java TreeView. Functional enrichment
analysis was performed using ToppGene.
Quantitative RT2-PCR Array Analysis of Cytokine, Chemokine,
and Chemokine Receptor Expression
RNA prepared from SCC cells was analyzed using the mouse cytokine and
chemokine RT2 Profiler PCR Array and that from isolated Tregs was analyzed
using the mouse chemokine and receptor array. Relative gene expression
(2DCt) values were log transformed, median centered, and subjected to hier-
archical clustering as for microarray analysis. An interactome of chemokine
ligands and receptors was constructed using the IUPHAR/BPS Guide to Phar-
macology database and curated from the literature, onto which expression
data for detected genes were mapped and visualized using Cytoscape.
Expression of selected cytokine and chemokine genes was assessed by stan-
dard quantitative RT-PCR.
shRNA-Mediated TGFb2 and Ccl5 Knockdown
Cells were subject to two rounds of lentiviral infection prior to selection with
puromycin. shRNA constructs used were part of the pLKO lentiviral TRC
library.
Preparation and Fractionation of Nuclei and Chromatin
Nuclei were prepared as described (Gilbert et al., 2003) but with a reduced
concentration (0.05%) of NP-40 in nuclei buffer B. Soluble chromatin was pre-
pared as described (Gilbert et al., 2004) and fractionated on a sucrose step
gradient to separate soluble and chromatin-associated nuclear proteins.
DNA was recovered from fractions and subjected to agarose gel electropho-
resis. Protein was purified using TCA precipitation. Samples were analyzed
by SDS-PAGE and blotted using anti FAK, HP1a, and histone H3 antibodies.
Proteomic Analysis of Nuclear FAK Protein Complexes
FAK nuclear protein complexes were subjected to on-bead proteolytic diges-
tion, desalting, and liquid chromatography-tandem mass spectrometry, as
described (Turriziani et al., 2014). For interaction network analysis, Ccl5 tran-
scription factors were extracted from the DECODE database and used to seeda network of 1,000 transcription factor-related proteins using the GeneMANIA
plugin in Cytoscape. Proteins specifically isolated in nuclear FAK protein com-
plexes were mapped onto the interactome, and those with physical or pre-
dicted direct or indirect interactions with Ccl5 transcription factors were
analyzed using the NetworkAnalyzer plugin in Cytoscape.
CD8 T Cell Fluorescent Immunohistochemistry
Tumors were removed 7 days post-implantation and frozen by submersing in
liquid nitrogen. Tumor sections were cut, processed and stained. They were
imaged using an Olympus FV1000 confocal microscope.
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